TransMedics Group is a medical devices business based in the US. TransMedics Group shares (TMDX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $134.24 – a decrease of 2.81% over the previous week. TransMedics Group employs 584 staff and has a trailing 12-month revenue of around $358.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $134.24 |
|---|---|
| 52-week range | $36.42 - $177.37 |
| 50-day moving average | $155.32 |
| 200-day moving average | $118.84 |
| Wall St. target price | $183.00 |
| PE ratio | 3453 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.04 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $134.235 from 2024-10-14
| 1 week (2024-10-09) | -2.15% |
|---|---|
| 1 month (2024-09-16) | -11.23% |
| 3 months (2024-07-16) | -11.58% |
| 6 months (2024-04-16) | 43.86% |
| 1 year (2023-10-16) | 206.33% |
|---|---|
| 2 years (2022-10-14) | 243.49% |
| 3 years (2021-10-15) | 405.59% |
| 5 years (2019-10-16) | 649.92% |
Valuing TransMedics Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of TransMedics Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
TransMedics Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3453x. In other words, TransMedics Group shares trade at around 3453x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
TransMedics Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $42.8 million.
The EBITDA is a measure of a TransMedics Group's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $358.8 million |
|---|---|
| Operating margin TTM | 10.94% |
| Gross profit TTM | $65.3 million |
| Return on assets TTM | 2.45% |
| Return on equity TTM | 1.79% |
| Profit margin | 0.84% |
| Book value | $5.70 |
| Market Capitalization | $4.6 billion |
TTM: trailing 12 months
We're not expecting TransMedics Group to pay a dividend over the next 12 months.
Over the last 12 months, TransMedics Group's shares have ranged in value from as little as $36.42 up to $177.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TransMedics Group's is 1.986. This would suggest that TransMedics Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
TransMedics Group, Inc. , a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.